2-piperidino-propionic acid ethyl ester | 63909-12-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-piperidino-propionic acid ethyl ester
• 英文别名: 2-Piperidino-propionsaeure-aethylester；ethyl 2-piperidinopropionate；Ethyl 2-piperidin-1-ylpropanoate
• CAS: 63909-12-6
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: ITYAIFQYIIUEEY-UHFFFAOYSA-N

物化性质

• 沸点：
  200 °C
• 密度：
  0.995±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-piperidino-propionic acid ethyl ester 在 乙醇 、 镍 作用下， 50.0 ℃ 、19.61 MPa 条件下， 生成 2-(piperidin-1-yl)propan-1-ol
  参考文献：
  名称：

  在阮内镍上将酯氢化为醇。

  摘要：

  DOI：

  10.1021/ja01204a032
• 作为产物：
  描述：

  哌啶 、 2-氯丙酸乙酯 生成 2-piperidino-propionic acid ethyl ester
  参考文献：
  名称：

  Bruehl, Chemische Berichte, 1876, vol. 9, p. 41

  摘要：

  DOI：

文献信息

• Alpha, alpha-diphenyl-beta-amino-propanols
  申请人：HOECHST AG

  公开号：US02827460A1

  公开（公告）日：1958-03-18

  The invention comprises compounds of the general formula <;FORM:0816578/IV (b)/1>; in which R1 and R2 are each a hydrogen atom or a halogen atom or a hydroxyl, methyl, methoxy, ethoxy or benzyloxy group, and <;FORM:0816578/IV (b)/2>; represents a hydrogenated heterocyclic ring, and acid addition salts of these compounds. The compounds are made by the reaction of a phenyl magnesium halide with a phenyl ethyl ketone or a propionic acid ester, substituted in the side chain by a saturated heterocyclic radical, the phenyl radicals being substituted, if required, by halogen atoms or methyl, methoxy or ethoxy groups or benzyloxy groups and, if desired, splitting off the benzyl radical from any benzyloxy group in the product by catalytic hydrogenation. The bases obtained may be connected to their acid addition salts with, for example, hydrochloric, hydrobromic, hydriodic, sulphuric, phosphoric, amidosulphonic, formic, acetic, malonic, succinic, lactic, malic, maleic, citric, benzoic, salicylic, p-aminosalicylic, aceturic, phenol-sulphonic, hydroxyethane-sulphonic or ethylene diamine tetracetic acid. The compounds are used as therapeutic agents. Examples describe the preparation of the 1 : 1 - diphenyl - 2 - piperidino -, 1 - phenyl - 1 - (para - benzyloxyphenyl) - 2 - piperidino -, 1 - phenyl - 1 - (para - hydroxyphenyl) - 2 - piperidino -, 1 : 1 - diphenyl - 2 - pyrrolidino -, 1 : 1 - diphenyl - 2 - morpholino -, 1 - phenyl - 1 - (4 - chlorophenyl) - 2 - piperidino -, 1 - phenyl - 1 - (3 : 4 - dimethoxyphenyl) - 2 - piperidino -, 1 - phenyl - 1 - (3 - ethoxyphenyl) - 2 - piperidino -, 1 - phenyl - 1 - (2 - methoxyphenyl) - 2 - piperidino -, 1 - phenyl - 1 - (3 - methylphenyl) - 2 - piperidino -, 1 - phenyl - 1 - (4 - methoxyphenyl) - 2 - piperidino -, 1 : 1 - diphenyl - 2 - (1 : 2 : 3 : 4) - tetrahydro - isoquinolino - and 1 : 1 - diphenyl - 2 - (a - methyl - piperidino) - propanols. Phenyl ethyl ketones, substituted by a basic group in the a -position, which are used as starting materials, are made by treating a propiophenone with bromine and reacting the product with a heterocyclic base. Specified ketones prepared by this method comprise a -piperidinopropiophenone and the corresponding p-benzyloxy and m-p-dimethoxy derivatives, a -pyrrolidino - propiophenone a - morpholino - propiophenone, a - (1 : 2 : 3 : 4)tetrahydro - isoquinoline - propiophenone and a - (a 1 - methylpiperidino) - propiophenone. Specifications 307,304, 307,307, [both in Class 2 (iii)], and 491,951, [Group IV], are referred to.

  该发明包括一般公式<;FORM:0816578/IV (b)/1>;中的化合物，其中R1和R2分别是氢原子或卤素原子或羟基、甲基、甲氧基、乙氧基或苄氧基，<;FORM:0816578/IV (b)/2>;代表氢化杂环环，并且这些化合物的酸盐。这些化合物是通过苯基镁卤化物与苯基乙基酮或丙酸酯的反应制备的，该酮在侧链上被饱和杂环基取代，苯基基团在需要时被卤素原子或甲基、甲氧基、乙氧基或苄氧基取代，如有需要，通过催化氢化从任何苄氧基的苄基基团中将苄基基团剥离。所得到的碱可以与它们的酸盐连接，例如，盐酸、溴化氢、碘化氢、硫酸、磷酸、酰胺磺酸、甲酸、乙酸、丙二酸、琥珀酸、乳酸、苹果酸、马来酸、枸橼酸、苯甲酸、水杨酸、对氨基水杨酸、乙酰基尿素、酚磺酸、羟基乙烷磺酸或乙二胺四乙酸。这些化合物被用作治疗剂。示例描述了1:1-二苯基-2-哌啶基-、1-苯基-1-(对-苄氧基苯基)-2-哌啶基-、1-苯基-1-(对-羟基苯基)-2-哌啶基-、1:1-二苯基-2-吡咯啉基-、1:1-二苯基-2-吗啉基-、1-苯基-1-(4-氯苯基)-2-哌啶基-、1-苯基-1-(3:4-二甲氧基苯基)-2-哌啶基-、1-苯基-1-(3-乙氧基苯基)-2-哌啶基-、1-苯基-1-(2-甲氧基苯基)-2-哌啶基-、1-苯基-1-(3-甲基苯基)-2-哌啶基-、1-苯基-1-(4-甲氧基苯基)-2-哌啶基-、1:1-二苯基-2-(1:2:3:4)-四氢异喹啉基-和1:1-二苯基-2-(α-甲基-哌啶基)-丙醇的制备。作为起始物质使用的α-位置上带有碱性基团的苯乙酮是通过用溴处理丙酮制备的，然后将产物与杂环碱反应得到。通过这种方法制备的指定酮包括α-哌啶基丙酮及相应的对-苄氧基和间-p-二甲氧基衍生物、α-吡咯啉基-丙酮、α-吗啉基-丙酮、α-(1:2:3:4)四氢-异喹啉基-丙酮和α-(α-甲基哌啶基)-丙酮。参考规范307,304，307,307，[均属于第2类(III)], 和491,951，[IV组]。
• Heterocycle derivatives and drugs
  申请人：——

  公开号：US20030022884A1

  公开（公告）日：2003-01-30

  The object of the invention is to provide an excellent compound as a drug. The invention relates to a heterocyclic compound shown by the following formula: A-B-D-E [1] wherein A is heteroaryl or its oxide; B is ethenylene; D is optionally substituted phenylene; and E is a group of the formula: 1 wherein G is optionally substituted phenyl; and R is heteroaryl or heteroarylmethyl, or a group of the formula: 2 wherein n is an integer of 1 to 5; R 5 and R 6 are same or different and are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, hydroxyalkyl, aminoalkyl; or R 5 and R 6 taken together with the adjacent nitrogen atom may form 5- to 7-membered cyclic amino group for —NR 5 R 6 or a salt thereof.

  本发明的目的是提供一种优良的化合物作为药物。该发明涉及一种由以下公式所示的杂环化合物：A-B-D-E [1]其中，A是杂芳基或其氧化物；B是乙烯基；D是可选取代的苯基；E是公式1的基团：其中，G是可选取代的苯基；R是杂芳基或杂芳基甲基，或者是公式2的基团：其中，n是1到5的整数；R5和R6相同或不同，且独立地选自由氢基、C1-C6烷基、羟基烷基、氨基烷基的群；或者R5和R6与相邻的氮原子一起形成5-至7-成员环氨基团的—NR5R6或其盐。
• The Chemistry of<i>N</i>-Substituted Benzotriazoles Part 23. Synthesis of Tertiary α-Amino Esters
  作者：Alan R. Katritzky、Laszlo Urogdi、Annie Mayence

  DOI：10.1055/s-1989-27244

  日期：——

  2-Dialkylaminoalkanoic esters 6 are prepared in good yield by the reaction of organozinc derivatives 5 with dialkylamino(1-benzo-triazolyl)acetic esters 4, obtained from the condensation of secondary amines 3 with ethyl glyoxylate 2 and benzotriazole (1).

  通过有机锌衍生物5与二烷基氨基(1-苯并三唑基)乙酸酯4的反应以良好收率制备2-二烷基氨基链烷酸酯6，所述二烷基氨基(1-苯并三唑基)乙酸酯4由仲胺3与乙醛酸乙酯2和苯并三唑(1)的缩合获得。
• Process for absorption of sulfur compounds from fluids using certain piperidines, piperazines, or anhydrides of monocarboxylic amino acids
  申请人：THE DOW CHEMICAL COMPANY

  公开号：EP0471592A2

  公开（公告）日：1992-02-19

  Sulfur dioxide is removed from a fluid containing SO2 by employing as an absorbent for the SO2 an aqueous solution of a compound represented by Formulae I, II or III : wherein each Y is independently -(CR22)- or -(CR2)= ; each R1, R2, R5 or R6 is independently hydrogen, an alkyl group ; an hydroxyalkyl group ; an aldehyde group ; a carboxylic acid group or salt thereof ; or an alkyl group containing at least one carboxylic acid ester, a carboxylic acid or salt thereof, ether, aldehyde, ketone, or sulfoxide group ; wherein at least one of R1 and R2 and at least one of R5 and R6 is a carbonyl-containing group ; each R3 or R4 is independently hydrogen ; an alkyl group ; a hydroxyalkyl group ; an aldehyde group ; a carboxylic acid or salt group ; or an alkyl, aryl, or aralkyl group containing at least one carboxylic ester, a carboxylic acid or salt, ether, aldehyde, ketones or sulfoxide group. The absorbent solution preferably can be thermally regenerated by heating to remove SO2.

  通过使用由式 I、II 或 III 所代表的化合物的水溶液作为二氧化硫的吸收剂，从含有二氧化硫的流体中去除二氧化硫： 其中每个 Y 独立地为-(CR22)-或-(CR2)＝；每个 R1、R2、R5 或 R6 独立地为氢、烷基、羟烷基、醛基、羧酸基或其盐、或含有至少一个羧酸酯、羧酸或其盐、醚、醛、酮或亚砜基的烷基；其中 R1 和 R2 中的至少一个以及 R5 和 R6 中的至少一个是含羰基的基团；每个 R3 或 R4 独立地是氢；烷基；羟烷基；醛基；羧酸或盐基；或含有至少一个羧酸酯、羧酸或盐、醚、醛、酮或亚砜基团的烷基、芳基或芳烷基。吸收剂溶液最好可以通过加热进行热再生，以去除二氧化硫。
• HETEROCYCLE DERIVATIVES AND DRUGS
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1238974A1

  公开（公告）日：2002-09-11

  The object of the invention is to provide an excellent compound as a drug. The invention relates to a heterocyclic compound shown by the following formula:         A-B-D-E   [1] wherein A is heteroaryl or its oxide; B is ethenylene; D is optionally substituted phenylene; and E is a group of the formula:    wherein G is optionally substituted phenyl; and R is heteroaryl or heteroarylmethyl, or a group of the formula: wherein n is an integer of 1 to 5; R5 and R6 are same or different and are independently selected from the group consisting of hydrogen, C1-C6 alkyl, hydroxyalkyl, aminoalkyl; or R5 and R6 taken together with the adjacent nitrogen atom may form 5- to 7-membered cyclic amino group for -NR5R6 or a salt thereof.

  本发明的目的是提供一种用作药物的优良化合物。 本发明涉及一种下式所示的杂环化合物： A-B-D-E [1] 其中 A 是杂芳基或其氧化物 B 是乙烯基 D 是任选取代的亚苯基；以及 E 是式中的一个基团 其中 G 是任选取代的苯基；和 R 是杂芳基或杂芳基甲基，或一个式中的基团： 其中 n 为 1 至 5 的整数；R5 和 R6 相同或不同，且独立选自由氢、C1-C6 烷基、羟基烷基、氨基烷基组成的组；或 R5 和 R6 与相邻的氮原子一起可形成 5 至 7 元环氨基基团为 -NR5R6 或其盐。